Titles
- Animal use in research: NIH should strengthen oversight of projects it funds at foreign facilities : report to congressional requesters1
- Annual status report information and other submissions for postmarketing requirements and commitments: using forms FDA 3988 and FDA 3989 : guidance for industry1
- Antibiotic resistance: Federal agencies have taken steps to combat the threat, but additional actions needed : testimony before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives1
- Antibiotic resistance: additional federal actions needed to better determine magnitude and reduce impact1
- Antimicrobial susceptibility test (AST) system devices: updating breakpoints in device labeling : guidance for industry and Food and Drug Administration staff1
- Antiviral drugs: Economic incentives and strategies for pandemic preparedness : report to congressional committees1
- Application of human factors engineering principles for combination products: questions and answers : guidance for industry and FDA staff1
- Arkansas Medicaid Fraud Control Unit: 2019 onsite inspection1
- Artificial intelligence in health care: benefits and challenges of machine learning technologies for medical diagnostics : report to congressional requesters1
- Assessing the California Children's Services Program1
- Assessing the credibility of computational modeling and simulation in medical device submissions: guidance for industry and Food and Drug Administration staff1
- Assessing the effects of food on drugs in INDs and NDAs: clinical pharmacology considerations1
- Assisted living in unlicensed housing: the regulatory experience of four states1
- Awaiting new Medicaid managed care rules: key issues to watch1
- Behavioral health and COVID-19: higher-risk populations and related federal relief funding : report to congressional committees1
- Behavioral health: Available workforce information and federal actions to help recruit and retain providers : report to congressional requesters1
- Benefit-risk assessment for new drug and biological products: guidance for industry1
- Best practices for convening a GRAS panel: guidance for industry1
- Billions in estimated Medicare Advantage payments from diagnoses reported only on health risk assessments raise concerns1
- Biomedical research: information on federal contributions to remdesivir : report to Congressional addressees1